Onkourologijos skyrius

Svarbiausios paskutinių metų publikacijos žurnaluose, įrašytuose į mokslinės informacijos instituto (Web of Science Clarivate Analytics) sąrašą:

2019-2023 m.

1. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR, ARAMIS Investigators Collaborators. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med. 2020; 383(11): 1040-1049. doi: 10.1056/NEJMoa2001342. (IF=74,699)
2. Stuopelyte K, Sabaliauskaite R, Bakavicius A, Haflidadóttir BS, Visakorpi T, Väänänen RM, Patel C, Danila DC, Lilja H, Lazutka JR, Ulys A, Jankevicius F, Jarmalaite S. Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. J Urol. 2020; 204(1):71-78. doi: 10.1097/ju.0000000000000803. (IF=5,925)
3. Drevinskaite M, Patasius A, Kevlicius L, Mickys U, Smailyte G. Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature. BMC Cancer. 2020; 20(1),162:1-6. doi: 10.1186/s12885-020-6648-3. (IF=3,15)
4. Šablinskas V, Bandzevičiūtė R, Velička M, Čeponkus J, Urbonienė V, Jankevičius F, Laurinavičius A, Dasevičius D, Steiner G. Fiber ATR infrared spectroscopy of kidney tissue during live surgery. J Biophotonics. 2020;13(7): 1-14. doi: 10.1002/jbio.202000018. (IF=1,205)
5. Vezelis A, Platkevicius G, Kincius M, Naruseviciute I, Ulys A, Jankevicius F. Prostate 3D ultrasound-guided imaging device (HistoScanning) performance detecting clinically significant prostate cancer. Journal of BUON. 2020;  25(1): 460-463. (IF=1,695)
6. Fizazi K, Kappeler C, Snapir A, Sarapohja T, Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I. Darolutamide in nonmetastatic, castration-resistant prostate cancer. New England journal of medicine. 2019; 380(13): 1235–1246. https://doi.org/10.1056/NEJMoa1815671 IF-79,260
7. Milonas D, Venclovas Ž, Gudinaviciene I, Auskalnis S, Zviniene K, Jurkiene N, Basevicius A, Patasius A, Jievaltas M, Joniau S. Impact of the 2014 international society of urological pathology grading system on concept of high-risk prostate cancer: comparison of long-term oncological outcomes in patients undergoing radical prostatectomy. Frontiers in Oncology. 2019; 9, 1272: 1–7. https://doi.org/10.3389/fonc.2019.01272 IF-4,137
8. Patasius A, Innos K, Barchuk A, Ryzhov A, Leja M, Misins J, Yaumenenka A, Smailyte G. Prostate cancer incidence and mortality in the Baltic states, Belarus, the Russian Federation and Ukraine. BMJ Open. 2019; 9(10): e031856: 1–7. https://doi.org/10.1136/bmjopen-2019-031856 IF-2,376
9. Patasius A, Kincius M, Kazlauskas E,Smailyte G. The role of androgen-deprivation therapy on suicide among patients with advanced prostate cancer: A nationwide population-based cohort study. Psychooncology. 2019; 28(10): 2098–2100. https://doi.org/10.1002/pon.5186 IF-3,430
10. Patasius A, Smailyte G. Changing stage distribution of prostate cancer in a Lithuanian population – evidence from national PSA-based screening programme. Int. J. Environ. Res. Public Health. 2019; 16(23): 356–387. https://doi.org/10.3390/ijerph16234856 IF-2,468
11. Patasius A, Urbonas V, Smailyte G. Skin Melanoma and Subsequent Risk of Prostate Cancer: A Lithuanian Cancer Registry Study. Int. J. Environ. Res. Public Health 2019; 16(20): 3915: 1–5. https://doi.org/10.3390/ijerph16203915 IF-2,468

Skyriaus mokslininkų paskelbti straipsniai – 2020-2023 m.

2020 m. mokslinės publikacijos
ISI straipsniai:

1. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR, ARAMIS Investigators Collaborators. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med. 2020; 383(11): 1040-1049. https://doi.org/10.1056/NEJMoa2001342.
2. Barisiene M, Bakavicius A, Stanciute D, Jurkeviciene J, Zelvys A, Ulys A, Vitkus D, Jankevicius F. Prostate Health Index and Prostate Health Index Density as Diagnostic Tools for Improved Prostate Cancer Detection. BioMed Research International. 2020; 2020(9872146): 1-15. https://doi.org/10.1155/2020/9872146
3. Patasius A, Kaceniene A, Ulys A, Stukas R, Smailyte G. Suicide risk among prostate cancer patients before and after the implementation of prostate-specific antigen-based prostate screening in Lithuania in 2006. Eur J Cancer Prev. 2020 Feb 7. doi: 10.1097/CEJ.0000000000000573
4. Stuopelyte K, Sabaliauskaite R, Bakavicius A, Haflidadóttir BS, Visakorpi T, Väänänen RM, Patel C, Danila DC, Lilja H, Lazutka JR, Ulys A, Jankevicius F, Jarmalaite S. Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. J Urol. 2020; 204(1):71-78 . https://doi.org/10.1097/ju.0000000000000803
5. Drevinskaite M, Patasius A, Kevlicius L, Mickys U, Smailyte G. Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature. BMC Cancer. 2020; 20(1),162:1-6. https://doi.org/10.1186/s12885-020-6648-3
6. Dulskas A, Patasius A, Kaceniene A, Linkeviciute-Ulinskiene D, Zabuliene L, Smailyte G. A Cohort Study of Antihyperglycemic Medication Exposure and Gastric Cancer Risk. J Clin Med. 2020;9(2), pii: E435: 1-8. https://doi.org/10.3390/jcm9020435
7. Dulskas A, Patasius A, Linkeviciute-Ulinskiene D, Zabuliene L, Smailyte G. Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival. International Journal of Environmental Research and Public Health. 2020; Volume: 17 Issue: 17, Article Number: 6016. DOI: 
8. Linkevičiūtė-Ulinskienė D, Patašius A, Zabulienė L, Stukas R, Smailytė G. Increased Risk of Site-Specific Cancer in People with Type 2 Diabetes: A National Cohort Study. International Journal of Environmental Research and Public Health. 2020; 17( 1),246:1-8. https://doi.org/10.3390/ijerph17010246
9. Linkeviciute-Ulinskiene D, Kaceniene A, Dulskas A, Patasius A, Zabuliene L, Smailyte G. Increased Mortality Risk in People with Type 2 Diabetes Mellitus in Lithuania. International Journal of Environmental Research and Public Health. 2020; Volume: 17 Issue: 18. Article Number: 6870. DOI: 10.3390/ijerph17186870
10. Undzyte G, Patasius A, Linkeviciute-Ulinskiene D, Zabuliene L, Stukas R, Dulskas A, Smailyte G. Increased kidney cancer risk in diabetes mellitus patients: a population-based cohort study in Lithuania. Aging Male. 2020; vol. 00, no. 00:1-6. https://doi.org/10.1080/13685538.2020.1755249
11. Vezelis A, Platkevicius G, Kincius M, Naruseviciute I, Ulys A, Jankevicius F. Prostate 3D ultrasound-guided imaging device (HistoScanning) performance detecting clinically significant prostate cancer. Journal of BUON. 2020;  25(1): 460-463. https://www.jbuon.com/archive/25-1-460.pdf

2022 m. ISI publikacijų sąrašas:

1. Klotz L, Grudén S, Axén N, Gauffin C, Wassberg C, Bjartell A, Giddens J, Incze P, Jansz K, Jievaltas M, Rendon R, Richard PO, Ulys A, Tammela TL. Liproca Depot: A New Antiandrogen Treatment for Active Surveillance Patients. European Urology Focus. 2022; Volume 8, Issue 1, January 2022, Pages 112-120. https://doi.org/10.1016/j.euf.2021.02.003
2. Makevičius J, Čekauskas A, Želvys A, Ulys A, Jankevičius F, Miglinas M. Evaluation of Renal Function after Partial Nephrectomy and Detection of Clinically Significant Acute Kidney Injury. Medicina 2022, 58(5), 667; https://doi.org/10.3390/medicina58050667
3. Snipaitiene K, Bakavicius A, Lazutka JR, Ulys A, Jankevicius F, Jarmalaite J. Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study. Prostate. 2022; 82(4): 475-482. doi: 10.1002/pros.24293
4. Kubiliūtė R, Žukauskaitė K, Žalimas A, Ulys A, Sabaliauskaitė R, Bakavičius A, Želvys A, Jankevičius F, Jarmalaitė S. Clinical signifcance of novel DNA methylation biomarkers for renal clear cell carcinoma. Journal of Cancer Research and Clinical Oncology. 2022; 148:361-375. doi: 10.1007/s00432-021-03837-7
5. Jonusas J, Drevinskaite M, Patasius A, Kincius M, Janulionis E, Smailyte G. Androgen-deprivation therapy and risk of death from cardio-vascular disease in prostate cancer patients: a nationwide lithuanian population-based cohort study. AGING MALE. 2022; 25(1): 173-179. DOI 10.1080/13685538.2022.2091130
6. Kaminskas A, Patasius A, Kincius M, Sapoka V, Zilevicius R, Garnelytė A, Dulskas A. A case report and review of the literature of penile metastasis from rectal cancer. Front. Surg. 2022; vol.9(814832): 1-10. htps://doi.org/10.3389/fsurg.2022.814832
7. Drevinskaite M, DadonieneJ, Miltiniene D, Patasius A, Smailyte G. Association between Androgen Deprivation Therapy and the Risk of Inflammatory Rheumatic Diseases in Men with Prostate Cancer: Nationwide Cohort Study in Lithuania. J. Clin. Med. 2022, 11(7), 2039; https://doi.org/10.3390/jcm11072039
8. Martin Bögemann, Neal D Shore, Matthew R Smith, Teuvo L J Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Thierry Lebret, Martin Schostak, Frank Verholen, Marie-Aude Le Berre, Shankar Srinivasan, Jorge Ortiz, Ateesha F Mohamed, Toni Sarapohja, Karim Fizazi. Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial on October 14, 2022. published in European Urology journal, (EURURO_9887).
9. Multiparametric MRI Fusion-Guided Prostate Biopsy for Detection of Clinically Significant Prostate Cancer Eliminates the Systemic Prostate Biopsy, Authors: Augustinas Matulevičius,Arnas Bakavičius ,4ORCID, Albertas Ulys, Mantas Trakymas, Jurgita Ušinskienė, Ieva Naruševičiūtė, Rasa Sabaliauskaitė, 2ORCID, Kristina Žukauskaitė, 2,Sonata Jarmalaitė , and Feliksas Jankevičius Published: 9 October 2022, Applied Sciences journal

2023 m. tarptautiniai pranešimai ir tezės:

1. Neal D. Shore1, Murilo Luz2, Albertas Ulys3, Jorge Ortiz4, Shankar Srinivasan4, Etah Kurland4, and Karim Fizazi5. Treatment duration and long-term safety and tolerability of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study. AUA 2023: American Urological Association, Meeting dates: April 28–May 1, 2023, Meeting location: Chicago, IL
2. Long-term safety and tolerability of darolutamide and duration of treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the ARAMIS Rollover Study. Neal D. Shore1, Murilo Luz2, Albertas Ulys3, Jorge Ortiz4, Shankar Srinivasan4, Etah Kurland4, and Karim Fizazi5. ASCO GU 2023:American Society of Clinical Oncology Genitourinary Cancers Symposium. Meeting dates: February 16-18, 2023. Meeting location: San Francisco, CA, USA
3. EAU23 38th Annual EAU Congress, Abstract ID:AM23-1120. Safety, tolerability, and duration of continued darolutamide treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): ARAMIS Rollover Study (ROS). Author: Fizazi K., Luz M., Ulys A., Ortiz J., Srinivasan S., Kurland E., Shore N. D. EAU23 Milan Abstract Submision

 

Straipsniai:

International Journal of Molecular Sciences (ISSN 1422-0067) Title: Urine molecular biomarkers for detection and follow-up of small renal masses. Authors: Algirdas Žalimas, Raimonda Kubiliūtė, Kristina Žukauskaitė, Rasa Sabaliauskaitė, Mantas Trakymas, Simona Letautienė, Edita Kaubrienė, Jurgita Ušinskienė, Albertas Ulys, Sonata Jarmalaitė
Received: 15 November 2022